What pharmacologic treatments are indicated for an adult with acute shortness of breath?

Pharmacologic Treatment for Acute Shortness of Breath in Adults

The pharmacologic treatment for acute shortness of breath depends entirely on the underlying cause, but for the most common etiologies: use short-acting beta-2 agonists (albuterol/salbutamol) with or without anticholinergics for COPD exacerbations or asthma, add systemic corticosteroids for moderate-to-severe cases, and consider antibiotics only when bacterial infection is suspected with purulent sputum.

Algorithmic Approach to Drug Selection

The key is rapid identification of the underlying cause, as this dictates treatment:

For COPD Exacerbations (Most Common Cause)

Initial bronchodilator therapy is the cornerstone. Short-acting inhaled β2-agonists (like albuterol), with or without short-acting anticholinergics (like ipratropium), are recommended as first-line treatment 1. This combination provides rapid bronchodilation and reduces dyspnea within minutes.

Add systemic corticosteroids for moderate-to-severe exacerbations. These improve lung function (FEV1), oxygenation, shorten recovery time, and reduce hospitalization duration 1. The evidence shows corticosteroids may reduce mortality within three months, though the confidence interval includes both benefit and harm (RR 0.77,95% CI 0.57 to 1.05), and they likely improve ventilator-free days by approximately 4 days 2.

Antibiotics should be added when indicated - specifically when there is increased sputum purulence suggesting bacterial infection. When appropriate, antibiotics shorten recovery time and reduce risk of early relapse, treatment failure, and hospitalization duration 1.

Critical pitfall: Avoid methylxanthines (theophylline) due to significant side effects without proven benefit 1.

For Asthma Exacerbations

The approach mirrors COPD management with some nuances:

• Short-acting beta-2 agonists are first-line (albuterol/salbutamol nebulized or via MDI)
• Systemic corticosteroids for all but the mildest cases
• Consider subcutaneous or intramuscular epinephrine only in severe, life-threatening cases where inhaled bronchodilators are insufficient, though evidence shows epinephrine may slightly increase early mortality compared to selective beta-agonists (RR 1.14,95% CI 0.91 to 1.42) 3

For Acute Respiratory Distress Syndrome (ARDS)

The pharmacologic evidence is limited and uncertain:

• Corticosteroids may reduce mortality (RR 0.77) and likely improve ventilator-free days by about 4 days, but evidence certainty is low 2
• Statins probably make little or no difference to mortality or ventilator-free days (moderate-certainty evidence) 2
• Beta-agonists should be avoided as they probably slightly increase mortality and reduce ventilator-free days 2
• Neuromuscular blocking agents for 48 hours in early, severe ARDS may improve mortality without additional harm, though this is primarily for mechanically ventilated patients 4

For Acute Pulmonary Embolism

While the 2026 PE guidelines 5 provide comprehensive management strategies, specific pharmacologic treatment focuses on anticoagulation rather than symptomatic relief of dyspnea. Supplemental oxygen should be provided as needed.

Key Clinical Distinctions

Differentiate COPD exacerbations from:

• Acute coronary syndrome
• Worsening congestive heart failure
• Pulmonary embolism
• Pneumonia

These conditions require entirely different pharmacologic approaches and missing them leads to inappropriate treatment and worse outcomes 1.

Severity-Based Treatment Algorithm

Mild exacerbations: Short-acting bronchodilators only

Moderate exacerbations: Short-acting bronchodilators PLUS antibiotics and/or oral corticosteroids

Severe exacerbations: All of the above PLUS hospitalization, consider non-invasive ventilation (NIV) as first-line for acute respiratory failure 1

Critical Pitfalls to Avoid

1. Don't delay bronchodilators while waiting for diagnostic confirmation in suspected obstructive disease
2. Don't use beta-agonists in ARDS - they worsen outcomes 2
3. Don't use methylxanthines in COPD - poor risk-benefit ratio 1
4. Don't give antibiotics reflexively - only when bacterial infection is suspected (purulent sputum) 1
5. Don't forget to initiate long-acting bronchodilators before hospital discharge in COPD patients 1